Eli Lilly's Stock Surge Was Predictable Based on Publicly Available Information
Over the past year, Eli Lilly (LLY) stock surged by about 52%, outperforming both its peers and the S&P 500. This growth was driven largely by strong financial performance and a new FDA-approved weight-management pill called Foundayo (orforglipron). In Q1 of 2026, revenue rose 56% year-over-year to $49 billion with non-GAAP earnings per share reaching $8.55. The launch of the oral medication was part of a long-discussed strategy by Eli Lilly's leadership, who had outlined plans for scaling production and addressing global demand as early as nine months before the stock began its upward trend. Foundayo became widely available in April 2026 with broad formulary access across major U.S. pharmacy benefit managers. Despite these clear signals, other large-cap pharmaceutical stocks like Merck (MRK) and Johnson & Johnson (JNJ) outperformed Eli Lilly during the same period. While the company's trajectory was evident from public data, market participants still found it challenging to gain a significant edge over peers.
Tickers: $AMGN $JNJ $LLY $MRK $PFE
Topics: Eli Lilly FDA approval LLY stock surge revenue growth weight management drug